Sahlgrenska University Hospital, Sweden Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4

Organization Overview

First Clinical Trial
2015
NCT02599038
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Department of Obstetrics and Gynaecology, Sahlgrenska University Hospital, Sweden | Department of Oncology, Sahlgrenska University Hospital, Sweden | Michael Fu | Sahlgrenska University Hospital, Gothenburg | Sahlgrenska University Hospital /Mölndal, Sweden | Sahlgrenska University Hospital, Sahlgrenska Academy, Gothenburg Sweden | Senior Consultant Anesthesia and Intensive Care, Sahlgrenska University Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 2)

Liver Diseases (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 7